Dermata Therapeutics, Inc.DRMANASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank59
5Y CAGR-2.9%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-2.9%/yr
Long-term compound
Percentile
P59
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 8.78% |
| Q2 2025 | 9.09% |
| Q1 2025 | 5.05% |
| Q4 2024 | 22.26% |
| Q3 2024 | -5.76% |
| Q2 2024 | -45.43% |
| Q1 2024 | 47.73% |
| Q4 2023 | 19.36% |
| Q3 2023 | 1.74% |
| Q2 2023 | -17.66% |
| Q1 2023 | 31.95% |
| Q4 2022 | -7.89% |
| Q3 2022 | -20.15% |
| Q2 2022 | -6.05% |
| Q1 2022 | -17.42% |
| Q4 2021 | 57.93% |
| Q3 2021 | 97.18% |
| Q2 2021 | -70.73% |
| Q1 2021 | 319.22% |
| Q4 2020 | -10.12% |
| Q3 2020 | 10.18% |
| Q2 2020 | -1.63% |
| Q1 2020 | 0.00% |